- Home
- MOLN vs HUCK Comparison
MOLN vs HUCK Comparison
Compare MOLN & HUCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.12
Company Overview
Basic Information| Metric | MOLN | HUCK |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Computer Software: Prepackaged Software |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 159.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MOLN | HUCK |
|---|---|---|
| Price | $3.56 | $3.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $10.36 | $4.17 |
| AVG Volume (30 Days) | 2.0K | ★ 759.8K |
| Earning Date | 10-29-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $318,857,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.00 | $1.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $3.52 | $2.98 |
| 52 Week High | $5.36 | $3.55 |
Technical Indicators
Market Signals| Indicator | MOLN | HUCK |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 34.32 |
| Support Level | N/A | $3.00 |
| Resistance Level | $4.59 | $3.45 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 5.13 | 29.47 |
Price Performance
Historical Comparison MOLN
HUCK
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.